Bidirectional Cohort Study on Improvement of Quality of Life in Patients After Coronary Intervention With Kuanxiong Aerosol

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Jun 26, 2024

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Meet the diagnostic criteria for coronary heart disease
• • Age 18\~80 years old, male and female, lower limbs can move freely
• • Patients with coronary angiography or coronary CT angiography indicating that the rate of coronary artery large vessel stenosis is greater than 80%
• • Patients with angina pectoris (angina pectoris frequency ≥3 times/week) after PCI according to the judgment of the treating physician
• • According to the doctor\'s judgment, patients who need to use conventional drugs (ACEI/ARB, β-blockers), and patients who need to use Kuanxiong Aerosol drugs on the basis of conventional drug therapy
• • Patients voluntarily sign informed consent
• Exclusion Criteria:
• • Allergic to ingredients contained in Kuanxiong Aerosol
• • Coronary artery bypass grafting was prepared during the trial
• • Blood lipid and uric acid exceeding 1.5 times the upper limit of normal reference value; Uncontrolled severe hypertension with systolic blood pressure \>180mmHg and/or diastolic blood pressure \>110mmHg
• • severe hepatic and renal insufficiency (ALT, AST or TBIL\>1.5 times the upper limit of normal reference value, Cr \>1.5 times the upper limit of normal reference value)
• • Malignant tumors
• • Severe arrhythmias (such as rapid atrial fibrillation, ventricular tachycardia, high atrioventricular block, etc.)
• • Women who are pregnant or trying to become pregnant
• • The researcher judged that it is not suitable to participate in this study